SCHEMBL6318930

SCHEMBL6318930

CSCCCNC(=O)c1c(-c2sccc2C)noc1N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.37
HDAC6 Q9UBN7 4/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC3 O15379 2/20 0.35
NCOR2 Q9Y618 2/20 0.35
HDAC4 P56524 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35
GAA P10253 2/20 0.35
TSHR P16473 1/20 0.34
ALDH1A1 P00352 4/20 0.32
CYP1A2 P05177 2/20 0.32
CYP2C9 P11712 2/20 0.32
CYP2C19 P33261 2/20 0.32
CYP2D6 P10635 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6324184 0.88 ALDH1A1 (0.44) POLBL3MBTL1HDAC6HDAC1HDAC3
SCHEMBL6317656 0.87 GAA (0.42) POLBL3MBTL1HDAC6HDAC1HDAC3
SCHEMBL6316236 0.86 GAA (0.41) POLBL3MBTL1HDAC6HDAC1HDAC3
SCHEMBL6317489 0.86 GAA (0.41) POLBL3MBTL1HDAC6HDAC1HDAC3
SCHEMBL6324005 0.86 GAA (0.41) POLBL3MBTL1HDAC6HDAC1HDAC3
SCHEMBL6318360 0.84 L3MBTL1 (0.57) POLBL3MBTL1GAATSHRALDH1A1
SCHEMBL6316911 0.83 MEN1 (0.45) POLBL3MBTL1HDAC6HDAC3NCOR2
SCHEMBL6321229 0.83 ALDH1A1 (0.40) POLBL3MBTL1GAATSHRALDH1A1
SCHEMBL6315241 0.83 L3MBTL1 (0.53) POLBL3MBTL1HDAC6HDAC1HDAC3
SCHEMBL6318335 0.81 NPC1 (0.50) POLBL3MBTL1GAATSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 POLB 872/4885L3MBTL1 4176/4885HDAC6 985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.